Literature DB >> 31313842

A loop involving NRF2, miR-29b-1-5p and AKT, regulates cell fate of MDA-MB-231 triple-negative breast cancer cells.

Anna De Blasio1, Riccardo Di Fiore1,2, Giovanni Pratelli1, Rosa Drago-Ferrante1, Christian Saliba3, Shawn Baldacchino4, Godfrey Grech4, Christian Scerri5, Renza Vento2, Giovanni Tesoriere2.   

Abstract

The present study shows that nuclear factor erythroid 2-related factor 2 (NRF2) and miR-29b-1-5p are two opposite forces which could regulate the fate of MDA-MB-231 cells, the most studied triple-negative breast cancer (TNBC) cell line. We show that NRF2 activation stimulates cell growth and markedly reduces reactive oxygen species (ROS) generation, whereas miR-29b-1-5p overexpression increases ROS generation and reduces cell proliferation. Moreover, NRF2 downregulates miR-29b-1-5p expression, whereas miR-29b-1-5p overexpression decreases p-AKT and p-NRF2. Furthermore, miR-29b-1-5p overexpression induces both inhibition of DNA N-methyltransferases (DNMT1, DNMT3A, and DNMT3B) expression and re-expression of HIN1, RASSF1A and CCND2. Conversely, NRF2 activation induces opposite effects. We also show that parthenolide, a naturally occurring small molecule, induces the expression of miR-29b-1-5p which could suppress NRF2 activation via AKT inhibition. Overall, this study uncovers a novel NRF2/miR-29b-1-5p/AKT regulatory loop that can regulate the fate (life/death) of MDA-MB-231 cells and suggests this loop as therapeutic target for TNBC.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  AKT; DNMTs; NRF2; miR-29b-1-5p; parthenolide; tumor suppressor genes

Mesh:

Substances:

Year:  2019        PMID: 31313842     DOI: 10.1002/jcp.29062

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

Review 1.  Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties.

Authors:  Daniela Carlisi; Marianna Lauricella; Antonella D'Anneo; Anna De Blasio; Adriana Celesia; Giovanni Pratelli; Antonietta Notaro; Giuseppe Calvaruso; Michela Giuliano; Sonia Emanuele
Journal:  Biomedicines       Date:  2022-02-21

Review 2.  DNMT3A and DNMT3B in Breast Tumorigenesis and Potential Therapy.

Authors:  Xiaxia Man; Qi Li; Baogang Wang; He Zhang; Songling Zhang; Ziyi Li
Journal:  Front Cell Dev Biol       Date:  2022-05-10

Review 3.  Role of Nrf2 Signaling Cascade in Breast Cancer: Strategies and Treatment.

Authors:  Hitesh Kumar; Rachna M Kumar; Devanjali Bhattacharjee; Preethi Somanna; Vikas Jain
Journal:  Front Pharmacol       Date:  2022-04-29       Impact factor: 5.988

4.  miR-29b restrains cholangiocarcinoma progression by relieving DNMT3B-mediated repression of CDKN2B expression.

Authors:  Kun Cao; Bo Li; Ye-Wei Zhang; Hui Song; Yi-Gang Chen; Yong-Jun Gong; Hai-Yang Li; Shi Zuo
Journal:  Aging (Albany NY)       Date:  2021-02-17       Impact factor: 5.682

Review 5.  The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer.

Authors:  Getinet M Adinew; Equar Taka; Patricia Mendonca; Samia S Messeha; Karam F A Soliman
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

Review 6.  The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy.

Authors:  Tao An; Huanhuan Yin; Yanting Lu; Feng Liu
Journal:  Drug Des Devel Ther       Date:  2022-04-29       Impact factor: 4.319

Review 7.  Metabolic Reprogramming in Triple-Negative Breast Cancer.

Authors:  Xiangyu Sun; Mozhi Wang; Mengshen Wang; Xueting Yu; Jingyi Guo; Tie Sun; Xinyan Li; Litong Yao; Haoran Dong; Yingying Xu
Journal:  Front Oncol       Date:  2020-03-31       Impact factor: 6.244

Review 8.  Involvement of NRF2 in Breast Cancer and Possible Therapeutical Role of Polyphenols and Melatonin.

Authors:  Alev Tascioglu Aliyev; Emiliano Panieri; Višnja Stepanić; Hande Gurer-Orhan; Luciano Saso
Journal:  Molecules       Date:  2021-03-25       Impact factor: 4.411

9.  Clues for Improving the Pathophysiology Knowledge for Endometriosis Using Serum Micro-RNA Expression.

Authors:  Yohann Dabi; Stéphane Suisse; Ludmila Jornea; Delphine Bouteiller; Cyril Touboul; Anne Puchar; Emile Daraï; Sofiane Bendifallah
Journal:  Diagnostics (Basel)       Date:  2022-01-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.